211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
416 articles with Daiichi Sankyo
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo.
While Daiichi Sankyo strives to help all patients, it is particularly focused on those with the greatest unmet need.
Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma
Daiichi Sankyo Company, Limited announced that valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, demonstrated promising response rates in a pivotal phase 2 study in Japanese patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer
New data from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd), continue to show encouraging durable tumor response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will present new breast cancer research data across its DXd ADC portfolio at the 2021 San Antonio Breast Cancer Symposium (#SABCS21) to be held December 7 to 10, 2021.
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Breast11 phase 3 trial evaluating the efficacy and safety of ENHERTU® (trastuzumab deruxtecan).
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global TROPION-Breast01 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced positive topline results from the global pivotal QuANTUM-First phase 3 trial evaluating quizartinib, a highly potent and selective FLT3 inhibitor, in patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
9/27/2021There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.
ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Detailed primary results from the positive, pivotal DESTINY-Lung01 phase 2 trial of ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, showed a robust and durable tumor response in previously-treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.
Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will present new research data across its antibody drug conjugate (ADC) portfolio in a broad range of cancers at the 2021 European Society for Medical Oncology (#ESMO21) Virtual Congress to be held September 16 to 21, 2021.
8/16/2021There was plenty of clinical trial updates last week. Here’s a look.
ImmVira announces MVR-C5252 targeting Glioblastoma has received the U.S. FDA clearance to proceed with clinical trial on August 6, 2021.
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
Positive topline results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, demonstrated superiority over trastuzumab emtansine.
The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU ® Initiated in Patients with HER2 Positive Metastatic Breast Cancer.